1 Improving FDA/Industry Interactions: Suggestions from FDA/CDER Statisticians Rafia Bhore, Ph.D. Janice Derr, Ph.D. FDA / CDER / Office of Biostatistics.
Implementation of a Validated Statistical Computing Environment Presented by Jeff Schumack, Associate Director – Drug Development Information September.
Challenges in Using a Formal Decision Analysis Approach to Medical Device Approval Larry Kessler, Sc.D. Director, Office of Science and Engineering Laboratories.
1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics.
U.S. Regulation of Drug Development and the Role of The Information Professional Alberto Grignolo, Ph.D. Corporate VP and General Manager PAREXEL Consulting.
1 Biomarkers and Clinical Care Lessons Learned from Case Studies: The Challenges and the Promise of Predictive Biomarkers Steven D. Averbuch, MD Vice President,
Biomarker Based PGx Strategies Rick Hockett, MD Chief Medical Officer Affymetrix.
Drug design and testing,. Drug Names Chemical name- describes its molecular structure and distinguishes it from other drugs.
Seniors.gov and Beyond Mark Pendleton, Senior Librarian for Outreach Services, Thomas Branigan Memorial Library Jim Veatch, Senior Librarian for Technical.
Changing Scene of Clinical Research Judy Stone, MD © Creative Commons Attribution- Noncommercial-Share Alike.
Janine Freeman, RD,LD,CDE UGA Extension Nutrition Specialist.
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events S. Percy Ivy, MD Associate Chief, Senior Investigator Investigational.